Henry Schein (HSIC)
NASDAQHealth CareMedical - DistributionSnapshot 2026-09-04
$89.81-1.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DistributionSnapshot 2026-09-04
Warn: Primary pillar under pressure — Maintain mid-single digit EBITDA growth in 2026: EBITDA margin 7.0% vs mid-single digit target.
Henry Schein grows sales about 3% to 5% yearly. Profit rises with mid-single digit EBITDA growth. EPS is on track for $5.3 in 2026. The company beats earnings and revenue estimates consistently.
Growth could slow if medical demand weakens. Management changes add uncertainty. Profit margins may compress if cost savings fall short.
The market prices in about 4% revenue growth and values the stock slightly below our fair value near $90. Our fair value is 6% above the Street median, reflecting confidence in steady growth and profit.
Breaks if: EBITDA growth falls below 4% in FY26
Breaks if: EPS guidance falls below $5.23 for FY26
Breaks if: YoY revenue growth falls below 3% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on steady sales and earnings growth. The current thesis state is intact, supported by recent strong financial results and management's commitment to growth targets.
The market currently reflects a neutral valuation, indicating that HSIC is priced relatively cheaply compared to its peers. There is a slight expectations gap, suggesting that while the fundamentals are solid, the stock is not overly expensive.
Management is on track to achieve its sales growth and earnings targets, with recent financial performance showing strong growth. However, there is a moderate risk due to the potential for economic downturns affecting the healthcare sector.
The long-term thesis hinges on maintaining strong execution and avoiding negative guidance changes. Additionally, the performance of sector bellwethers could influence HSIC's momentum in the coming months.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat and reaffirmed EPS guidance support the thesis. However, the exit of three executives may disrupt strategic initiatives.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, HSIC's fundamentals appear solid, but the company must navigate potential economic headwinds. Not investment advice.